Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Payables (2016 - 2025)

Standard Biotools (LAB) has disclosed Payables for 16 consecutive years, with $6.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 39.42% to $6.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.6 million, a 39.42% decrease, with the full-year FY2024 number at $5.0 million, down 45.33% from a year prior.
  • Payables was $6.6 million for Q3 2025 at Standard Biotools, down from $7.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $13.1 million in Q1 2024 to a low of $5.0 million in Q4 2024.
  • A 5-year average of $9.5 million and a median of $9.3 million in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: plummeted 51.19% in 2023, then skyrocketed 115.11% in 2024.
  • Standard Biotools' Payables stood at $10.6 million in 2021, then decreased by 25.35% to $7.9 million in 2022, then rose by 16.7% to $9.2 million in 2023, then crashed by 45.33% to $5.0 million in 2024, then surged by 31.1% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Payables are $6.6 million (Q3 2025), $7.3 million (Q2 2025), and $11.8 million (Q1 2025).